Preparation method of mesenchymal stem cells applied to menopausal symptoms

Abstract

The invention discloses a preparation method of mesenchymal stem cells applied to menopausal symptoms. The preparation method comprises the following steps: S1, separating; S2, initial treatment; S3,filtering; S4, inoculating and culture; S5, passage; S6, cell cryopreservation; and S7, cell thawing. The invention aims at carrying out uniform and systematic monitoring on the whole process from rawmaterial collection to completion of cell preparation, and the quality from screening before collection of the placenta tissue to preparation of cells into intermediate goods and final products of finished products is completely controlled.

Description

technical field [0001] The invention relates to the field of cell biology, in particular to a method for preparing mesenchymal stem cells applied to menopausal syndrome. Background technique [0002] Stem cells are a kind of pluripotent cells with self-replication ability. Under certain conditions, it can differentiate into a variety of functional cells. Stem cells are divided into embryonic stem cells (embryonic stem cells, ES cells) and adult stem cells (somatic stem cells) according to their developmental stages. Stem cells are divided into three categories according to their developmental potential: totipotent stem cells (TSCs), pluripotent stem cells (pluripotent stem cells), and unipotent stem cells (unipotent stem cells). Stem cells are not fully differentiated and immature cells, which have the potential to regenerate various tissues and organs and the human body. They are called "universal cells" in the medical field. Stem cells exist in all multicellular tissues...

AI Technical Summary

Problems solved by technology

[0008] In recent years, with the development of gene therapy and stem cell technology, more and more attention has been paid to the use of stem cell technology to replace hormone therapy; Laparoscopic ovarian orthotopic injection of mesenchymal stem cells / cytokines in the treatment of premature ovarian failure has achieved certain curative effect, but the curative effect is not very satisfactory and the effective rate is low, specifically manifested in:

[0009] First of all, mesenchymal stem cells after venous infusion tend to adhere to clusters, and unfiltered infusion can easily cause pulmonary vein embolism, manifested as shortness of breath, cyanosis, restlessness, and convulsions, and there are also cases of hemiplegia caused by cardiovascular and cerebrovascular stroke;

[0010] Secondly, although mesenchymal stem cells have low immunogenicity and no or low expression of class II antigens, a certain proportion of leukocyte antibodies will still be produced after repeated intravenous infusion of mesenchymal stem cells, which is proportional to the amount of input cells per time. Antigen-antibody reactions can lead to reactions such as low-grade fever, fatigue, and respiratory distress. Intravenous infusion of cells or factors has a limited amount of homing, which also affects the curative effect to a certain extent.

[0011] Intervention therapy generally needs to be opened in the abdomen, and the catheter is inserted into the blood vessel or lesion under the laparoscope. The curative effect of one-time intervention is limited, and repeated interventions repeatedly bring iatrogenic trauma to patients, which is unacceptable and difficult to popularize

[0012] Therefore, so far, there is no definite and effective method to restore ovarian function, so the etiology of premature ovarian failure is complex and difficult to treat, and modern medicine has not yet made breakthroughs.

Images